AEGAegon Ltd.
The schedule
- Tue20Oct
Anticipated developments regarding U.S. regulatory scrutiny of annuity sales and fiduciary rules affecting the Transamerica business.
- Thu12Nov
Aegon's Q3 interim trading update, primarily focused on capital ratios and commercial momentum rather than full IFRS financials.
- Thu18Feb
Full-year results and management's key opportunity to reset multi-year dividend and share buyback expectations.
- Sun9May
- Sun8Aug
- Thu19Aug
Aegon's delayed Q1 2026 results release, which will serve as a critical update on early-year capital generation and Transamerica unit performance.
Past
- Sun9Aug
Actual outcome: Bull · $9.45 at outcome
AEG reported in-line EPS of 0.26, matching estimates, and provided stable guidance on core life insurance margins. Strategic partnerships, including a major middle office mandate win and a strategic partnership with Creativeman Productions, reinforced long-term growth prospects, driving the stock higher despite the flat price action.
Quick-turnaround Q2 results providing full H1 2026 financials, focusing on core life insurance margins and progress on the Standard Life transaction.
- Mon15Jun
Actual outcome: Bull · $8.52 at outcome
Aegon updated investors on its capital return and strategy, highlighting a £2 billion transaction with Standard Life to support deleveraging and buybacks while refocusing on its U.S. business. Additionally, shareholders approved a final 2025 dividend of EUR 0.21 per share and extended the CEO's term. Despite these positive structural and capital deployment updates, the market reaction was muted, leaving the stock flat as the developments were likely already priced in.
Management update on the ongoing share buyback program and capital deployment strategy.